Insider Selling: Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock

Posted by Geri Gentry on Aug 16th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) EVP Shannon Parisotto sold 3,714 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total value of $1,038,657.24. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,344,325.62. This trade represents a 43.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Down 0.6%

CRL stock opened at $279.70 on Friday. The firm has a fifty day moving average price of $224.87 and a 200 day moving average price of $191.33. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $288.02. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market cap of $13.35 billion, a PE ratio of -57.67, a price-to-earnings-growth ratio of 2.90 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the firm earned $3.12 earnings per share. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently made changes to their positions in CRL. Invesco Ltd. boosted its stake in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares during the period. Victory Capital Management Inc. raised its position in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares during the period. Ameriprise Financial Inc. lifted its stake in Charles River Laboratories International by 1,491.1% in the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares during the last quarter. Amundi lifted its stake in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after purchasing an additional 492,301 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $96,765,000. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research report on Monday, August 10th. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research note on Monday, July 20th. Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research report on Thursday, August 6th. Royal Bank Of Canada upped their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, Mizuho set a $264.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $255.65.

View Our Latest Research Report on CRL

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.